Pharma Mirror Magazine

DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders

March 17, 2021

Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration

Pharma Interest

PCR Buffer: Polymerase Chain Reaction Mediator

March 15, 2021

PCR buffer is a vital component of the Polymerase Chain Reaction, also called molecular photocopying. The reaction has helped scientists

Pharmaceutical News

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

March 12, 2021

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa

Pharmaceutical News

CPhI Report forecasts explosion of contract services growth due to surging INDs and 75 FDA approvals by 2025

March 10, 2021

A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare

Pharmaceutical News

Syngenta and Botanical Solution Inc. (BSI) team up for a new botanical-based biofungicde rollout !

March 10, 2021

Davis, CA: Botanical Solution Inc. (BSI) and Syngenta, two companies which are closely aligned in their commitment to innovation and sustainability in

Pharma Interest

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

March 8, 2021

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against

MORE NEWS

DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders

PCR Buffer: Polymerase Chain Reaction Mediator

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

CPhI Report forecasts explosion of contract services growth due to surging INDs and 75 FDA approvals by 2025

Syngenta and Botanical Solution Inc. (BSI) team up for a new botanical-based biofungicde rollout !

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy